Conference Day 1

Day One

Tuesday June 22 2021

9:15 am Chair’s Opening Remarks

  • Dexiu Bu Senior Principal Scientist, Novartis

9:20 am Immunotherapy for Multiple Myeloma: What Have We Learned

  • Adam Cohen Assistant Professor – Medicine, University of Pennsylvania


  • Multiple Myeloma is characterized by progressive immune dysregulation, especially in relapsed/refractory disease
  • Despite this fact, immunotherapies including monoclonal antibodies/ antibody-drug conjugates, bispecific T-cell engagers, and CAR T cells, many of which target BCMA, have high response rates in heavily-pretreated patients
  • Understanding predictors of response and mechanisms of resistance will be key to developing strategies to further improve depth and duration of response in myeloma

9:50 am The Evolution of Belamaf & What Comes Next

  • Brandon Kremer Medical Director, Clinical Development, GlaxoSmithKline


  • BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
  • Preclinical data suggest potential for enhanced clinical activity of belantamab mafodotin when administered in combination with other standard-of-care and novel anti-myeloma agents
  • Clinical trials are ongoing to evaluate the safety and efficacy of belantamab mafodotin-containing combination regimens in first- and second-line multiple myeloma

10:20 am Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed &/or Refractory Multiple Myeloma (RRMM)

  • Raluca Verona Senior Director, Head of Immune Oncology & Translational Research, JnJ

10:50 am AMG 701 – A BCMA-Targeting BiTE® Molecule for the Treatment of Multiple Myeloma – From Bench to Bedside


  • Analyzing nonclinical in vitro and in vivo characterization
  • Determination of a Safe FiH Start Dose
  • Evaluating results of a Dose Escalation FiH Phase 1 Study

11:20 am Virtual Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the BCMA field and establish meaningful business relationships to pursue for the rest of the conference.

Exploring the Various Modalities that Target BCMA in Multiple Myeloma

12:00 pm Managing Biomarkers in Multiple Myeloma Clinical Trials: Considerations for Assay Development, Specimen Diversity & Logistics


· MM offers a large diversity of content-rich specimens
· To maximize biomarker output, specimen specific pre-analytic processes are important. Specifically,

-Decalcification procedures for bone marrow biopsies are necessary to minimize genomic data loss
-Enrichment methodologies for bone marrow aspirates can stabilize and purify specimen populations

12:30 pm Sharing Novel BCMA-Targeted CAR-T Cells


  • Discussing the advantages of transposons and Tscm for CAR-T cells
  • Reviewing P-BCMA-101 autologous CAR-T cells
  • Reviewing P-BCMA-ALLO1 allogeneic CAR-T cells

1:00 pm Serum BCMA: A Promising New Biomarker for Multiple Myeloma and CLL Patients

1:30 pm Benchmarking T Cell-Redirecting Therapies for Cancer: Comparing BCMAxCD3 Bispecifics & BCMA CAR T Cells


• Understanding the two competing platforms that exist for redirecting T cells to recognize and kill tumors: Bispecific antibodies and chimeric antigen receptor (CAR) T cells
• Presenting the preclinical in vitro and in vivo models developed to mechanistically compare these two technologies and discussing our findings as well as the clinical implications

2:00 pm Lunch

Exploring the Various Modalities that Target BCMA in Multiple Myeloma

3:00 pm An Enhanced Antibody, SEA-BCMA, Building Toward a Versatile Therapeutic for Multiple Myeloma Patients


  • SEA-BCMA is an investigational nonfucosylated Ab with enhanced ADCC activity that blocks BCMA cell signaling
  • SEA-BCMA induces prolonged survival and durable tumor regressions in preclinical MM xenografts, even in the absence of immune effectors
  • SEA-BCMA combines effectively with MM standard of care in preclinical models

Determining Mechanisms of Relapse

3:30 pm A Potent & Safe BCMA CAR T-cell Therapy with Optimized Human scFv for Relapsed/Refractory Multiple Myeloma

  • Hong Ma Senior Vice President - Clinical Development, CARSgen Therapeutics


  • Reporting on the safety and efficacy of CAR-BCMA T cells (CT053) utilizing a newly identified, fully-human BCMA-specific scFv with finetuned binding affinity
  • Discussing how CT053 showed low-level CD3 autophosphorylation and induced relatively low-level IL-6 secretion while displaying potent preclinical antitumor activities
  • Presenting the results in three studies (CG studies in China, LUMMICAR-1 in China and LUMMICAR-2 in US and Canada)

4:00 pm Fully-human, Variable Heavy Chain Only Anti-BCMA CAR T-cell Therapy for Multiple Myeloma: A Novel Approach to Limit Relapse After Therapy


• Understanding why anti-BCMA CAR T cells have powerful activity against multiple myeloma but to date this therapy is no curative
• CAR T cells can be eliminated by recipient anti-CAR immune responses, a potential mechanism of relapse after therapy
• Reviewing how fully-human, variable heavy chain only CAR T cells may reduce potential immune responses directed at CAR T cells; a phase I clinical trial testing this technology has demonstrated deep and durable responses

4:30 pm Session Reserved for Noopur Raje

  • Noopur Raje Director - Multiple Myeloma Program & Professor - Medicine, Massachusetts General Hospital

5:00 pm Chair’s Closing Remarks

  • Dexiu Bu Senior Principal Scientist, Novartis

5:10 pm Scientific Poster Session


After the formal presentations have finished, the learning and networking carries on. The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on the latest advancements in the BCMA field.

5:30 pm End of Conference Day One